M C Cavallo1, V Sepe2, F Conte3, M Abelli4, E Ticozzelli4, A Bottazzi5, P M Geraci6. 1. CeRGAS, Università Commerciale Luigi Bocconi, Milan, Italy. 2. Unit of Nephrology, Dialysis, Transplantation, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. Electronic address: vincenzo.sepe@gmail.com. 3. Unit of Nephrology and Dialysis, Ospedale di Cernusco sul Naviglio, Cernusco sul Naviglio, Italy. 4. Unit of Transplantation Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 5. Intensive Care Unit 2, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 6. Transplantation Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Abstract
INTRODUCTION: Kidney transplantation represents the best therapeutic option for patients with end-stage renal disease (ESRD), providing the best outcomes for survival, quality of life, and cost-effectiveness. To increase kidney donations, in 2007, the Italian IRCCS Policlinico San Matteo Foundation in Pavia designed and conducted Programma Alba, a protocol for organ donation after cardiac death (DCD). This study evaluated the costs and health outcomes of DCD transplantation and in all types of transplants compared with current clinical practice. PATIENTS AND METHODS: A Markov-based model was used to assess costs and health outcomes for new ESRD patients for 2008 to 2013. A health care founder perspective was used. Data sources were the Italian National Institute of Statistics and the Lombardy Registry of Dialysis and Transplantation. A microcosting analysis was performed to calculate costs related to clinical pathways for DCD. We assessed costs, survival, quality-adjusted survival, and cost-effectiveness. FINDINGS: Changing the actual practice pattern for new patients with ESRD and increasing the availability of kidneys from DCD to 10 extra transplants per year will induce an incremental cost per quality-adjusted life-year of €4255. Increases in transplantation to reach an extra 10% by transplant type would result in reduced costs and increased patient survival and quality of life compared with the current scenario. INTERPRETATION: Our data show that increasing DCD transplants would result in a cost-effective policy to expand the kidney donor pool compared with current ESRD treatment patterns. Italian policies should make an effort to increase transplant rates to optimize cost-effectiveness in ESRD service supply.
INTRODUCTION: Kidney transplantation represents the best therapeutic option for patients with end-stage renal disease (ESRD), providing the best outcomes for survival, quality of life, and cost-effectiveness. To increase kidney donations, in 2007, the Italian IRCCS Policlinico San Matteo Foundation in Pavia designed and conducted Programma Alba, a protocol for organ donation after cardiac death (DCD). This study evaluated the costs and health outcomes of DCD transplantation and in all types of transplants compared with current clinical practice. PATIENTS AND METHODS: A Markov-based model was used to assess costs and health outcomes for new ESRDpatients for 2008 to 2013. A health care founder perspective was used. Data sources were the Italian National Institute of Statistics and the Lombardy Registry of Dialysis and Transplantation. A microcosting analysis was performed to calculate costs related to clinical pathways for DCD. We assessed costs, survival, quality-adjusted survival, and cost-effectiveness. FINDINGS: Changing the actual practice pattern for new patients with ESRD and increasing the availability of kidneys from DCD to 10 extra transplants per year will induce an incremental cost per quality-adjusted life-year of €4255. Increases in transplantation to reach an extra 10% by transplant type would result in reduced costs and increased patient survival and quality of life compared with the current scenario. INTERPRETATION: Our data show that increasing DCD transplants would result in a cost-effective policy to expand the kidney donor pool compared with current ESRD treatment patterns. Italian policies should make an effort to increase transplant rates to optimize cost-effectiveness in ESRD service supply.
Authors: Long Jiang Zhang; Jin Peng; Jiqiu Wen; U Joseph Schoepf; Akos Varga-Szemes; L Parkwood Griffith; Yuan Meng Yu; Shu Min Tao; Yan Jun Li; Xue Feng Ni; Jian Xu; Dong Hong Shi; Guang Ming Lu Journal: Eur Radiol Date: 2018-04-17 Impact factor: 5.315
Authors: Mohsen Yaghoubi; Sonya Cressman; Louisa Edwards; Steven Shechter; Mary M Doyle-Waters; Paul Keown; Ruth Sapir-Pichhadze; Stirling Bryan Journal: Appl Health Econ Health Policy Date: 2022-08-09 Impact factor: 3.686
Authors: Alexander V van Schoonhoven; Judith J Gout-Zwart; Marijke J S de Vries; Antoinette D I van Asselt; Evgeni Dvortsin; Pepijn Vemer; Job F M van Boven; Maarten J Postma Journal: PLoS One Date: 2019-09-06 Impact factor: 3.240
Authors: Xin Zheng; Min Li; Pan Wang; Xiangnan Li; Qiang Zhang; Song Zeng; Tao Jiang; Xiaopeng Hu Journal: BMC Med Imaging Date: 2021-04-07 Impact factor: 1.930
Authors: Hanno Maassen; Henri G D Leuvenink; Harry van Goor; Jan-Stephan F Sanders; Robert A Pol; Cyril Moers; H Sijbrand Hofker Journal: Transpl Int Date: 2022-02-09 Impact factor: 3.782
Authors: Hanno Maassen; Koen D W Hendriks; Leonie H Venema; Rob H Henning; Sijbrand H Hofker; Harry van Goor; Henri G D Leuvenink; Annemieke M Coester Journal: PLoS One Date: 2019-11-19 Impact factor: 3.240